Abstract. We have generated a novel monoclonal antibody (mAb), OCAb9-1, which specifically binds to various types of cancer cell lines, but not to normal cells. According to the results of immunoaffinity chromatography, LC-MS/MS analysis, co-immunoprecipitation, and RNA interference studies, the target protein of OCAb9-1 is the epithelial cell adhesion molecule (EpCAM). EpCAM is a type I transmembrane glycoprotein which is highly expressed in epithelial-transformed neoplasia and tumor-initiating cells (TICs). However, regulation of EpCAM gene expression in tumors and its role in tumorigenesis are not fully understood. In the present study, we show that EpCAM expression is elevated in several cancer cell lines and tumor tissues. Loss-of-function experiments were performed to demonstrate that EpCAM negatively regulates expression of p53 and p21, and promotes tumor cell growth, colony formation, migration and invasion. The median overall survival of tumor-bearing mice treated with OCAb9-1 was significantly higher than that of PBS-treated mice. Moreover, we report that the interplay between SUZ12 and JMJD3 results in dynamic regulation of lysine 27 trimethylation of histone 3 (H3K27me3). Taken together, our findings suggest that the anti-EpCAM mAb may be suitable for use in cancer diagnosis, prognosis, imaging and therapy. Furthermore, EpCAM overexpression in cancer cells is strongly associated with tumor progression, and may be regulated by epigenetic mechanisms.
Introduction
Colorectal cancer is one of the most common cancers worldwide, with over 1.2 million new cancer cases and 608,700 related deaths reported worldwide (1, 2) . One contributing factor appears to be high expression levels of the cell surface protein EpCAM, which correlate with increased tumorigenesis in a range of carcinomas, including breast, colon, and head and neck squamous cell carcinoma (HNSCC) (3, 4) . Therefore, we have been investigating the biological function, gene regulation and clinicopathological significance of this protein.
EpCAM (CD326) is a homophilic, calcium-independent cell adhesion molecule (a type I transmembrane glycoprotein) of 39-42 kDa, encoded by the TACSTD1 gene on the long arm of chromosome 2p21 (5, 6) . Overexpression of EpCAM in epithelial cancers is associated with enhanced proliferation and malignant potential (7, 8) , and levels of EpCAM expression are correlated with de-differentiation and malignant proliferation of epithelial cells (9, 10) . Moreover, EpCAM is frequently detected in cancer-initiating cells (11, 12) and normal stem or progenitor cells (13) (14) (15) (16) (17) . As it is often highly expressed in cancer cells, EpCAM has gained attention as a potential target for diagnostic and antibody-based immunotherapies for a spectrum of malignancies (18) (19) (20) (21) (22) (23) .
Most colorectal cancer cases (75-80%) occur sporadically as a result of the accumulation of both mutations and epigenetic modifications of several genes (24) . One of the most studied epigenetic markers in colorectal cancer is DNA methylation, which involves covalent addition of methyl groups to the 5' position of cytosine residues, usually at cytosine-phosphateguanine (CpG) dinucleotides (25) . Over the last few years, much has been learned about the effects of DNA methylation and histone modifications on the regulation of gene expression and genome function. Several studies have reported on the DNA methylation status of the EpCAM promoter in lung, colon, prostate, liver, bladder, ovary and breast cancer cells and tissues (26) (27) (28) (29) . For various tumor types, EpCAM overexpression is associated with DNA hypomethylation of the promoter; furthermore, treatment of EpCAM-negative cells with a DNA methylation inhibitor induced EpCAM expression (26, 27, 30) .
The ever-increasing number of genes reported to exhibit epigenetic alterations in cancer emphasizes the importance of these modifications for future diagnosis, prognosis, and prediction of response to therapies (31) . Therefore, research is currently ongoing to develop rapid, cost effective and reproducible tools for the detection of epigenetic markers (31) . In the present study, we investigated epigenetic mechanisms underlying the overexpression of EpCAM in colon cancer. A better understanding of the regulation of EpCAM gene expression may provide new opportunities for cancer therapy, based on reversing epigenetic markers.
To clarify the biological significance of EpCAM in tumor progression, we examined EpCAM expression in a series of cancer cell lines and tumor tissues. In addition, we addressed whether epigenetic transitions in the 5' flanking region of the EpCAM promoter are responsible for altered expression in colorectal cancer cells, by evaluating CpG status using methylation-specific PCR (MSP) and bisulfite sequencing, and histone modification by chromatin immunoprecipitation (ChIP). Our data suggest that epigenetic upregulation of EpCAM may contribute to tumor progression.
Materials and methods
Cell lines and culture. The following human cell lines were used: oral cancer (SAS), nasopharyngeal carcinoma (NPC) (32) . Primary cultures of NNM were generated from biopsies of patients with nasal polyposis (34, 35) . The use of NNM was approved by the Human Subject Research Ethics Committee, Institutional Review Board, Academia Sinica (AS-IRB01-06008). Human umbilical vein endothelial cells (HUVECs) were purchased (Lonza, Walkersville, MD, USA) and cultured in EBM-2 media (Lonza). The human oral cancer cell line SAS was obtained from the Japanese Collection of Research Bioresources (Tokyo, Japan). The cells were cultivated in Dulbecco's modified Eagle's media (DMEM) supplemented with 10% fetal bovine serum (FBS), at 37˚C with 5% CO 2 . Other cell lines were purchased from ATCC and were cultured in Dulbecco's modified Eagle's media (DMEM) supplemented with 5 or 10% FBS (Gibco, Grand Island, NY, USA), at 37˚C in a humidified incubator containing 5% CO 2 . Cells were cultured in accordance with protocols obtained from the ATCC and were passaged for fewer than 6 months after resuscitation.
Generation of monoclonal antibodies and purification of
IgG. Monoclonal antibodies against human cancer cells were generated following a standard procedure (36) , with slight modifications (37, 38) . Briefly, female BALB/cJ mice [4-6-week-old; National Laboratory Animal Center (NLAC), Taipei, Taiwan] were immunized intraperitoneally with SAS four times at 3-week intervals. On day 4 after the final boost, splenocytes were harvested from the immunized mouse spleen and fused with NSI/1-Ag4-1 myeloma cells using 50% polyethylene glycol (Gibco). Fused cells were suspended in DMEM supplemented with hypoxanthine-aminopterinthymidine (HAT; Sigma, St. Louis, MO, USA) and hybridoma cloning factor (ICN Biomedicals, Aurora, OH, USA) and were then plated onto 96-well plates. These hybridomas, which were positive for SAS but negative for NNM, were then subcloned by limited dilution, before being preserved in liquid nitrogen.
Ascites were produced in pristane-primed BALB/cJ mice, and mAbs were purified using a protein G Sepharose 4G gel (GE Healthcare Biosciences, Pittsburgh, PA, USA).
ELISA. Cell culture (96-well) plates (Corning Costar, St. Louis, MO, USA) were seeded with SAS, NPC, H441, HCT116, SKOV-3, MCF7, BxPC-3, NNM or HUVECs cells. The plates were fixed with 2% paraformaldehyde, and blocked with 1% bovine serum albumin (BSA). OCAb9-1 was added to the plates, which were then incubated for 1 h. The plates were subsequently washed with PBS containing 0.1% (w/v) Tween-20 (PBST 0.1 ), followed by incubation with horseradish peroxidase-conjugated anti-mouse IgG (115-035-062; Jackson ImmunoResearch Laboratories, West Grove, PA, USA) for 1 h. After washing, the plates were incubated with substrate solution (o-phenylenediamine dihydrochloride; Sigma, P6787). The reaction was stopped by the addition of 3 N HCl, and signals were detected using a microplate reader at 490 nm.
Flow cytometry. SAS, HCT116 and NNM cells were dissociated with 0.25% trypsin-EDTA (1 mM) (Invitrogen) for 1-3 min. Cells were washed with cell sorting buffer (PBS containing 1% fetal calf serum) and then incubated for 1 h at 4˚C in cell sorting buffer with OCAb9-1 at dilutions ranging from 0.00001 to 1 µg/ml. Cells were then incubated with phycoerythrin (PE)-conjugated goat anti-mouse IgG (dilution 1:250; 111-166-144; Jackson ImmunoResearch Laboratories) for 30 min at 4˚C. After a final wash, the cells were re-suspended with 1% FBS in PBS and analyzed by flow cytometry (BD Biosciences, San Jose, CA, USA).
Immunofluorescent staining. Cells cultured on coverslips were fixed in 2% paraformaldehyde for 20 min before being washed, and subsequently blocked with 1% BSA in PBS for 30 min. Cells were incubated at room temperature (RT) with OCAb9-1 (1 µg/ml) in 1% BSA for 1 h. The cover slide was incubated with Alexa Fluor 488 goat anti-mouse antibodies (Invitrogen) for 1 h at RT. Nuclei were counterstained with 4' ,6-diamidino-2-phenylindole (DAPI 1:500). The fluorescent images were observed under a fluorescent microscope (A-Zeiss).
Identification of the target protein. SAS cells were lysed with lysis buffer [50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1% Nonidet P-40 (NP-40)] supplemented with a protease inhibitor cocktail tablet (Roche Diagnostics, Indianapolis, IN, USA). The supernatant was applied to protein G sepharose (GE Healthcare Biosciences) coupled to OCAb9-1. After washing, the proteins bound to OCAb9-1 were eluted with elution buffer (0.2 M glycine, pH 2.5, 150 mM NaCl and 1% NP-40), and the eluates were neutralized with 1 M Tris-HCl, pH 9.1 (37) . The eluates were then separated by SDS-PAGE. The band of interest was cut from the gel, reduced with 50 mM dithioerythritol (DTE) in 25 mM ammonium bicarbonate (ABC) at pH 8.5 for 1 h at 37˚C, and alkylated with 100 mM iodoacetamide (IAA) in ABC for 1 h at RT. After washing with 50% acetonitrile in ABC, the gel was soaked in 100% acetonitrile and incubated with 0.02 µg trypsin for 16 h at 37˚C. The digested peptides were extracted with 50% acetonitrile in 5% TFA, and concentrated using a Concentrator (Eppendorf, Hamburg, Germany). The sample was subjected to LC-MS/MS sequencing, as performed by the Core Facility for Proteomics and Structural Biology Research at Academia Sinica.
Lentivirus production. Small hairpin RNA vectors for EpCAM silencing (5'-GCAAATGGACACAAATTACAA-3'; 5'-GCC GTAAACTGCTTTGTGAAT-3') were obtained from the National RNAi Core Facility (Academia Sinica, Taiwan). To generate stable EpCAM-knockdown cell lines, HEK293T packaging cells were co-transfected with a packaging plasmid (pCMV-∆R8.91), and envelope (pMDG) and hairpin pLKORNAi vectors using a PolyJet Transfection kit (SignaGen Laboratories, Ijamsville, MD, USA). At 48-h post-transfection, virus-containing supernatants were collected, mixed with fresh media containing polybrene (8 µg/ml) and incubated with target cells for another 48 h. Transduced cells were selected with puromycin (2 µg/ml) for 7 days.
Immunohistochemistry and evaluation of EpCAM expression.
EpCAM expression was detected by immunohistochemistry using the murine mAb OCAb9-1. Tumor tissues from human tissue arrays (Pantomics Inc., San Franscico, CA, USA) were incubated with the mAb OCAb9-1 at a concentration of 1 µg/ml for 1 h at RT. After being washed with PBST 0.1 , sections were treated with the polymerbased Super Sensitive IHC detection system (BioGenex, San Ramon, CA, USA). In brief, sections were incubated with Super Enhancer reagent for 20 min at RT and were then thoroughly rinsed three times with PBST 0.1 for 5 min each. Sections were subsequently treated with Poly-HRP reagent for 30 min at RT. Diaminobenzidine hydrochloride (DAB) (0.02%) containing 0.03% H 2 O 2 was used as a chromogen to visualize peroxidase activity. The preparations were lightly counterstained with hematoxylin, mounted with Permount (Fisher Scientific, Pittsburgh, PA, USA) and examined by light microscopy. A human cancer tissue microarray (TMA MTU391 or TMA COC961) was purchased from Pantomics, Inc., and expression of EpCAM was analyzed using HistoQuest software (TissueGnostics, Vienna, Austria). Human cancer tissue microarrays (TMAs) were purchased from Biomax. The use of TMAs was approved by the Human Subject Research Ethics Committee, Institutional Review Board, Academia Sinica (AS-IRB02-100067). EpCAM overexpression was defined by calculating a total staining score as the product of a proportion score (0-3) and an intensity score (0-3). The proportion score indicated the estimated fraction of positively-stained tumor cells (0, <10%; 1, <10-30%; 2, 30-50%; 3, >50%), while the intensity score indicated the estimated staining intensity (0, no staining; 1, weak; 2, moderate; 3, strong). The total score ranged from zero to nine. Samples were divided into two groups based on their EpCAM total score: group 1, low level expression (score <3); group 2, high level expression (previously described as overexpression, score ≥3) (39) .
Immunoprecipitation and western blot analysis. Cells were extracted with RIPA buffer [0.01 M sodium phosphate (pH 7.2), 150 mM NaCl, 2 mM EDTA, 50 mM NaF, 1% NP-40, 1% sodium deoxycholate, and 0.1% SDS] supplemented with a protease inhibitor mixture tablet (Roche Diagnostics) and centrifuged at 20,000 x g for 30 min at 4˚C. An equal amount of proteins (1 mg) were incubated with Dynabeads protein G (Invitrogen Dynal AS, Oslo, Norway) conjugated to OCAb9-1 antibody (3 µg) at 4˚C for 4 h. The mixtures were washed twice with ice-cold RIPA buffer and boiled in SDS-sample buffer. For western blotting, cells were extracted using RIPA buffer containing protease inhibitor cocktail (Roche, Basel, Switzerland). Equal amounts of protein were separated on SDS-PAGE and then transferred to PVDF membranes (Millipore, Bedford, MA, USA). The membrane was blocked with 1% BSA, and incubated with OCAb9-1 (1 µg/ml), antiEpCAM mAb (1:100 dilution; 1144-1; Epitomics, Burlingame, CA, USA), anti-p53 (0.1 µg/ml; OP43L; Calbiochem, Merck KGaA, Darmstadt, Germany), anti-p21 Waf1/Cip1 (1:1000 dilution; #2946; Cell Signaling Technology, Inc. Danvers, MA, USA), or α-tubulin (1:5000; Sigma) mAbs overnight. Membranes were then incubated with HRP-conjugated secondary antibodies (1:10,000; Jackson ImmunoResearch) for 1 h at room temperature, and protein expression was detected using an ECL kit (Millipore, Temecula, CA, USA).
RNA extraction and quantitative real-time RT-PCR.
Total RNA samples were prepared from cell lines using Ultraspec RNA isolation reagent (Biotecx Laboratories, Inc., Houston, TX, USA). RNA was reverse transcribed into cDNA using SuperScript III RNase H reverse transcriptase (Invitrogen, Carlsbad, CA, USA), according to the manufacturer's instructions. The forward and reverse primers for PCR are listed in Table I . Quantitative RT-PCR was performed using the LightCycler 480 II system (Roche Applied Science, Indianapolis, IN, USA). Expression levels of each gene were normalized to the expression level of GAPDH in the same sample. The reactions were performed in triplicate, and SD values were calculated.
Surface plasmon resonance. The affinities of murine antibodies were determined by surface plasmon resonance (Biacore T200; Biacore). EpCAM antigen was immobilized on a Series S Sensor Chip CM5 (Biacore) and injected at a flow rate of 10 µl/min. The mAb were diluted in HBS-EP buffer (Biacore) and injected at a flow rate of 30 µl/min for 1.5 min; mAb were then allowed to dissociate over 5 min. Before injection of each mAb, the surface was regenerated by injection of a solution of 10 mM glycine HCl, 0.2 M NaCl (pH 2.5). The data were analyzed using BIAevaluation software with a global fit 1:1 binding model.
Animal model of colon carcinoma metastasis.
The NOD/SCID mice were obtained from Jackson Laboratory (Bar Harbor, ME, USA) and were bred in the core facility of ICOB in Acdemia Sinica. HCT116 cells (1x10 6 cells/mouse) were injected into 6-week-old female NOD/SCID mice through the lateral tail vein. Mice were then treated with PBS and OCAb9-1. The dosage was 20 mg/kg on days 1 and 4. Mouse body weight and survival rate were measured twice a week (n=8). Mice were monitored every day and given soft diet to decrease the suffering of the mice. For mouse survival study, the tumor size was not appropriate to use as a humane endpoint. Alternatively, we used humane endpoints by judgment of the mouse weight loss (>20% of body weight) or mouse activity assessment (hunching, stationary, ruffling and poor grooming). Animal care was carried out according to guidelines established by Academia Sinica, Taiwan. The protocol was approved by the Committee on the Ethics of Animal Experiments of Academia Sinica (AS IACUC: 11-04-166).
Genomic DNA isolation, bisulfite modification and methylation specific PCR (MSP).
The CpG methylation status of the EpCAM promoter was evaluated by MSP. Genomic DNA was purified using the Wizard Genomic DNA purification kit (Promega, Madison, WI, USA). The bisulfite reaction was performed on 500 ng DNA, which was further subjected to bisulfite modification using the EZ DNA methylation kit, according to the manufacturer's directions (Zymo Research, Orange, CA, USA). The primers used for MSP amplification are listed in Table I . PCRs were performed in a thermocycler (Bio-Rad Laboratories, Richmond, CA, USA) for 40 cycles at 95˚C for 1 sec, 51˚C for 5 sec, and 72˚C for 25 sec, followed by a final extension at 72˚C for 10 sec to amplify bisulfitemodified DNA.
Bisulfite sequencing. Genomic DNA (500 ng) was treated with the EZ DNA modification kit (Zymo Research), according to the manufacturer's recommendations. Completely methylated and unmethylated control genomic DNAs were purchased from Qiagen (Valencia, CA, USA). The promoter regions of the EpCAM gene were amplified by PCR. Primer sequences used for PCR amplification are listed in Table I . The PCR products were purified using the QIAquick PCR purification kit (Qiagen), following the manufacturer's instructions. The purified PCR products were then subcloned into a TA cloning vector (pGEM-T Easy vector; Promega). Clones (twenty for control DNA and ten for each sample) were verified by sequencing with the T7 universal primer.
Chromatin immunoprecipitation (ChIP) and quantitative real-time PCR.
ChIP was performed as previously described (40) with some modifications. Briefly, ChIP assays were carried out on 1x10 5 HCT116 and NNM cells. The protein-DNA complexes were fixed using 1% formaldehyde, and the cross-linking reaction was quenched by adding glycine to a final concentration of 200 mM. The chromatin complexes were then sonicated to an average size of 250 bp using a Misonix Sonicator 3000. Protein A beads (Invitrogen) were incubated at 4˚C for 2 h with one of the following antibodies: anti-H3K4me3 (2.4 µg; ab8580; Abcam, Cambridge, MA, USA), anti-H3K9K14Ac (2.4 µg; 06-599; Upstate-Millipore, Charlottesville, VA, USA), anti-H3K27me3 (5 µg; ab6002; Abcam), anti-H3K9me3 (5 µg; 07-442; Upstate), anti-SUZ12 (2 µg; ab12073; Abcam) or anti-JMJD3 (4 µg; AP1022a; Abgent, San Diego, CA, USA). The antibodies were subsequently incubated with chromatin for a further 2 h. The bound fraction was isolated using Protein A beads according to the manufacturer's instructions, and the immunocomplexes were subsequently subjected to reverse crosslinking. The immunoprecipitated DNA was recovered using a PCR purification kit (Qiagen) according to the manufacturer's instructions, and target DNA was detected by real-time PCR using the LightCycler 480 System (Roche). The amplification primers are listed in Table I . For each sample, PCR analysis was performed in triplicate, and the bound fraction was compared with input DNA from 1x10 4 cells. For each gene, the ratio of immunoprecipitated DNA to input DNA (IP/Input) was determined. To obtain relative occupancy values, the IP/Input was further normalized to the level observed at a control region, HBB (H3K4me3, H3K9K14Ac and SUZ12) or GAPDH (H3K27me3, H3K9me3, JMJD3 and EpCAM), which was defined as 1.0.
Statistical analysis. All data were derived from at least three independent experiments. Values are expressed as the mean ± SD. Experimental test conditions were compared with the respective control by Student's t-test, unless otherwise specified. Differences were considered significant at * P<0.05, ** P<0.01 or *** P<0.001. Survival analyses were performed using Kaplan-Meier survival curves, and significant differences between groups were tested using the log-rank test. Correlation coefficients were assayed by Spearman's analysis.
Results

Generation and characterization of mAbs recognizing cancer cells.
We generated more than 8,000 hybridoma clones, twelve clones exhibiting relatively high reactivity against SAS cells were selected (Table II) . Cellular ELISA and western blotting revealed that OCAb9-1 specifically recognized several human cancer cells (SAS, NPC, HCT116, H441, MCF7, BxPC-3 and SKOV-3), but not normal cells, such as NNM or HUVECs (Fig. 1A and B) . Closer examination by immunofluorescent analysis (Fig. 1C) and FACS (Fig. 1D) revealed that this mAb exhibited extremely high cell surface binding activity for Table II . Summary of the main features of mAbs against cancer cells. Table III . Expression of OCAb9-1 target in colon carcinoma. Table II . Further experiments using various human cancer tissue arrays confirmed that OCAb9-1 was able to specifically recognize human cancer tissues of different origins including oral, colon, ovarian, breast, pancreatic and uterus cancer, but not matched normal tissues ( Fig. 2A) . Thirty-three samples of colon adenocarcinoma tissue specimens from a colon cancer tissue array stained positively for OCAb9-1, while five normal colon tissues showed little staining ( Fig. 2B and Table III ). All 33 patients in a colon cancer microarray were analyzed, and most of these samples exhibited intense OCAb9-1 staining in the majority of tumor cells (Table III) .
Cell lines ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
OCAb9-1 target expression ----------------------------------------------
To identify the target molecule of OCAb9-1, SAS cell lysates were prepared and purified by OCAb9-1-conjugated immunoaffinity chromatography. Silver staining and western blotting demonstrated that OCAb9-1 recognized a target protein with a molecular weight of 39 kDa (Fig. 2C) . LC-MS/MS was used to identify this protein as human EpCAM (Fig. 2D) . The specificity of OCAb9-1 for EpCAM was confirmed by immunoprecipitation assays and western blotting with a commercial rabbit anti-EpCAM antibody, 1144-1 (Fig. 2E ). OCAb9-1 has a very high affinity for EpCAM, with a kinetic constant of 71.68 pM (Table IV) .
Inhibition of cancer cell growth in vitro by EpCAM shRNA.
The functional role of EpCAM in tumorigenesis was evaluated by knocking down its expression in SAS cells with EpCAM shRNA (Fig. 3A) . Western blotting (Fig. 3B) and FACS (Fig. 3C ) revealed a dramatic decrease in OCAb9-1 after EpCAM knockdown, thereby confirming the specificity of OCAb9-1 against EpCAM. Knockdown of EpCAM also suppressed growth rate (Fig. 3D ), colony formation (Fig. 3E) , migration ( Fig. 3F ) and the invasion ability (Fig. 3G) of SAS tumor cells. We next examined whether knockdown of EpCAM affected the expression of the p53 and p21 genes in SAS cells. Western blotting revealed that the p53 and p21 proteins were increased following EpCAM knockdown (Fig. 3H) , confirming earlier findings (41) . In summary, EpCAM knockdown inhibits cancer cell growth, migration and invasion, and upregulates pro-apoptotic gene expression in vitro. These results suggest that EpCAM may be a potential target for cancer therapy.
EpCAM methylation status in HCT116 and NNM. It remains unclear why EpCAM is overexpressed in HCT116 cells, more insights in the epigenetic regulation of the EpCAM gene promoter itself are required. Accessibility of transcription factors to the specific binding sites within the EpCAM gene depends on the chromatin structure, which is affected by DNA methylation and histone modifications (42) . We examined the methylation status of EpCAM promoter regions in both Primers for MSP and bisulfite sequencing were designed to target the 5' flanking region of the EpCAM promoter. MSP assays were performed to determine the methylation status of EpCAM for both HCT116 and NNM. We used commercially available completely methylated and completely unmethylated DNAs as controls for the primers. As shown in Fig. 4B , PCR using primers against unmethylated sequences amplified DNA from both HCT116 and NNM cells, whereas PCR using primers against methylated sequences resulted in trace amounts of DNA from NNM cells only.
To further determine the CpG island methylation status of the EpCAM gene promoter in HCT116 and NNM cells, we used bisulfite-assisted genomic sequencing. Clone sequencing analysis revealed that 98% of the CpG sites of the HCT116 clones and 84% of those of the NNM clones are unmethylated (Fig. 4C) . These results indicate that EpCAM silencing in NMM may not be due to changes in the methylation status of the EpCAM promoter in these cells.
Histone modification of the EpCAM promoter region in HCT116 and NNM.
To address whether there is an association between EpCAM expression and chromatin architecture in cancer cells, we examined the histone modification profile of the region encompassing the EpCAM promoter in HCT116 and NNM cells. To this end, we performed ChIP assays against four histone modifications (lysine 4 trimethylation of histone 3 (H3K4me3), lysine 9/14 acetylation of histone 3 (H3K9K14Ac), lysine 27 trimethylation of histone 3 (H3K27me3), and lysine 9 trimethylation of histone 3 (H3K9me3)) at four regions of the EpCAM promoter: upstream distal (-630 to -550) and proximal (-354 to -273), and downstream proximal (+426 to +539) and distal (+835 to +967) relative to the transcription start site (TSS). In HCT116 cells, H3K4me3 occupancy was enhanced at both proximal and distal regions downstream of TSS, but unaffected at proximal and distal regions upstream of TSS, as compared to that in NNM cells (Fig. 5A ). H3K9K14Ac association has been reported to be enriched at the 5' end of active genes, and to be strongly correlated with H3K4me3 (43) . Consistent with these earlier findings, the acetylation level of H3K9K14 was high in both proximal and distal downstream regions of TSS in EpCAM-positive HCT116, as observed for H3K4me3 (Fig. 5B) .
Previous studies have suggested that there is a correlation between H3K27me3 and gene repression (44) . Indeed, our study found H3K27me3 signals to be elevated at all upstream and downstream regions of the silent EpCAM promoter of NNM cells (Fig. 5C) . Methylation of lysine 9 of histone 3 is known to facilitate formation of heterochromatin, and elevated levels of H3K9me3 at promoter sequences have been associated with suppression of gene expression (44, 45) . We observed enhanced H3K9me3 occupancy at all four promoter regions in NNM as compared to HCT116 cells (Fig. 5D ). Our profiling of histone modifications by ChIP suggests that chromatin remodeling in the 5' flanking region of the EpCAM promoter may be responsible for the increase in EpCAM expression in HCT116 colon cancer cells.
We subsequently investigated whether recruitment of the polycomb protein SUZ12 underlies the increased methylation of H3K27 at the EpCAM promoter in NNM cells. As hypothesized, we detected higher SUZ12 signals in NNM than in HCT116 cells, both upstream and downstream of the EpCAM promoter (Fig. 5E ). These results suggest that EpCAM is controlled by the PRC2 complex, the major histone methyltransferase responsible for H3K27me3. Conversely, we observed a corresponding rise in JMJD3 binding at both proximal and distal regions downstream of the EpCAM TSS in HCT116 cells (Fig. 5F ), which coincided with the reduction of H3K27me3 (Fig. 5C ); this suggests a direct causal relationship between JMJD3 recruitment and H3K27 demethylation. These findings indicate that EpCAM expression in HCT116 cells is maintained by the loss of H3K27me3 and SUZ12 at the promoter of the EpCAM gene, and this is accompanied by an increase in JMJD3.
OCAb9-1 increases the survival rate of an animal model of colon cancer metastasis. The OCAb9-1 exhibited high specificity against EpCAM in colorectal cancer tissue (Fig. 2B) , we then proceeded to use OCAb9-1 in an animal model of colon carcinoma metastasis to investigate whether targeting EpCAM can prolong the survival of tumor-bearing mice. NOD/SCID mice were injected intravenously with HCT116 cells; mice bearing circulating HCT116 cells were intravenously treated with OCAb9-1 or an equivalent volume of PBS at 24 and 96 h after cell injection (antibody was delivered at 20 mg/kg/dose, for a total dose of 40 mg/kg). The median overall survival of tumor-bearing mice treated with OCAb9-1 was significantly higher than that of PBS-treated mice (Fig. 6) . The median overall survival of tumor-bearing mice was 122 or 84 days after treatment with OCAb9-1 or PBS, respectively (Fig. 6) . The difference in overall survival (OS) between the PBS and OCAb9-1 treatment groups (as determined using Kaplan-Meier curves) was found to be statistically significant (log-rank test; P= 0.014). The data provided direct evidence demonstrating that by targeting EpCAM can directly increase the median overall survival of metastatic tumor-bearing mice.
Discussion
The importance of EpCAM expression in tumor-initiating cells (TICs) or cancer stem cells (CSC) has been previously emphasized (46) . EpCAM exerts oncogenic effects on members of the wnt pathway, accounting for the high expression of EpCAM in many cancers, particularly TICs from various tumor entities (4, 47) . Colon cancer cells exhibit the highest level of EpCAM expression of any cancer, with the frequency for any subgroup being typically >90% (22) . Such a frequency of EpCAM enrichment in colorectal cancer at all stages of the disease makes colon cancer an ideal indication for anti-EpCAM-based therapies. Novel human anti-EpCAM or bispecific T-cell engaging antibodies may facilitate the development of an anti-EpCAM-based therapy for the treatment of cancer.
The current standard treatment for stage IV metastatic colorectal cancer involves the use of a combination of chemotherapeutic agents, including irinotecan, fluorouracil, and leucovorin (IFL), following surgical resection (48) . In stage III colon cancer, adjuvant therapy with edrecolomab plus fluorouracil-based therapy did not have a statistically significant effect on the overall survival of patients (49) . Adecatumumab (MT201), which is a fully human IgG1 mAb targeting EpCAM, has activity independent of K-Ras status. A phase II study in patients with metastatic breast cancer confirmed the overall safety and feasibility of single-agent treatment with adecatumumab (21) . Despite effective adjuvant treatment, many patients experience disease recurrence and death from disseminated disease. Thus, there is a need for more effective adjuvant treatments for colon cancer. We previously generated a novel antibody, OCAb9-1, which has been shown to exhibit high specificity to EpCAM. To evaluate the therapeutic efficacy of OCAb9-1 as a potential treatment for colon cancer, we treated human colon cancer with the antibody in metastatic animal models (Fig. 6) . The metastatic colon cancer-bearing mice treated with OCAb9-1 exhibited markedly prolonged median overall survival, indicating the significant therapeutic potential of the antibody. The expression of EpCAM has been used to recognize hepatic stem cells in fetal, postnatal and adult humans (13) (14) (15) , and is believed to be useful in the selection of tumor-initiating cells (11, 12) . Normal pancreatic tissues also express EpCAM ( Fig. 2A) , accounting for the pancreatitis observed in certain clinical trials of anti-EpCAM based therapeutics (50, 51) . In our previous study, we found that EpCAM signaling triggered by the release of extracellular domain of EpCAM (EpEX) and intracellular domain of EpCAM (EpICD) is observed in cancer cells, but not in normal healthy cells (52) . Hence, it is possible that pancreatitis may be avoided by novel therapeutic antibody that triggers cancer cell apoptosis by inhibiting EpCAM signaling (52) without affecting EpCAM function in healthy pancreatic cells.
Post-translational modifications (including phosphorylation, acetylation, ubiquitination and methylation) of histone tails have been confirmed to be dynamic regulators of gene expression. The polycomb group (PcG) proteins are important chromatin modifiers that play a pivotal role in the epigenetic regulation of the development, differentiation, and maintenance of cell fates (53) . Polycomb repressive complex 2 (PRC2) mediates transcriptional repression by catalyzing the tri-methylation of lysine 27 on histone H3 (H3K27me3) (54) . Suppressor of Zeste 12 homolog (SUZ12) is essential for methylation of H3K27me3 by PRC2 (55) (56) (57) . The recent identification of the JmjC-domain-containing histone lysine demethylase JMJD3 suggests that there may be positive and negative regulators simultaneously controlling chromatin structure dynamics through histone methylation. JMJD3 specifically removes trimethyl marks from H3K27 in mammalian cells to antagonize PcG gene silencing and permit gene transcription (58, 59) . These findings suggest that EpCAM may be regulated by both SUZ12 and JMJD3 during tumor progression. Our investigation into the epigenetic regulation of EpCAM in HCT116 cells indicates that the expression of EpCAM was not regulated by DNA methylation, a process that irreversibly silences genes (Fig. 4) . Instead, we found that there is a drastic reduction in histone active markers, namely H3K4 trimethylation and H3K9 acetylation, and a clear enhancement of repressive markers, H3K9 and H3K27 trimethylation, at the EpCAM promoter in NNM cells (Fig. 5) . Our results suggest that the dynamic expression pattern of EpCAM during tumor progression is carefully modulated by histone modifying enzymes, such as SUZ12 and JMJD3, but not by DNA methylase; as a consequence, plasticity of EpCAM expression is maintained.
